Brad Youngblood

Dr. Youngblood joined Allakos in 2015 and has held positions of increasing responsibility throughout his tenure. He has over 10 years of experience in pre-clinical and antibody development and is an author and inventor on numerous publications and patents related to inhibitory receptor biology and function. Before joining Allakos, Dr. Youngblood was a scientist in the cancer immunology group at OncoMed Pharmaceuticals.

Dr. Youngblood holds a Bachelor of Science from Baylor University and PhD in Cell Biology and Biochemistry from Texas Tech University Health Sciences Center.